Infectious lung complications in patients with HIV/AIDS

Current Opinion in Pulmonary Medicine

Volumn 11, Issue 3, 2005, Pages 203-207

  Boyton, Rosemary J ^a,b,c  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Highly active antiretroviral therapy; HIV AIDS; Pneumonia

Indexed keywords

ANTIRETROVIRUS AGENT; AZITHROMYCIN; CLARITHROMYCIN; COTRIMOXAZOLE; MACROLIDE; PLACEBO; PNEUMOCOCCUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; ATYPICAL MYCOBACTERIOSIS; BACTERIAL PNEUMONIA; CLINICAL FEATURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION SENSITIVITY; LUNG INFECTION; MYCOBACTERIUM TUBERCULOSIS; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; REVIEW; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VIRUS PNEUMONIA;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; FEMALE; GREAT BRITAIN; HUMANS; LUNG DISEASES, FUNGAL; MALE; PNEUMONIA, BACTERIAL; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TUBERCULOSIS, PULMONARY;

EID: 17744378803     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Stebbing J, Gazzard B, Douek D. Where does HIV live? N Engl J Med 2004; 350:1872-1880.
2. Brenchley J, Schacker T, Ruff L, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominately in the gastrointestinal tract. J Exp Med 2004; 200:749-759.
3. Picker L, Hagen S, Lum R, et al. Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive Simian Immunodeficiency Virus infection. J Exp Med 2004; 200:1299-1314.
4. Leonard M, Larsen N, Drechsler H, et al. Increased survival of persons with tuberculosis and human immunodeficiency virus infection, 1991-2000. Clin Infect Dis 2002; 34:1002-1007.
5. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
6. Dye C, Scheele S, Dolin P, et al. Global burden of tuberculosis. Estimated incidence, prevalence, and mortality by country. JAMA 1999; 282:677-686.
7. Whalen C, Nsubuga P, Okwera A, et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000; 14:1219-1228.
8. Hung C, Chang S. Impact of highly active antiretroviral therapy on incidence and management of human immunodeficiency virus-related opportunistic infections. J Antimicrob Chemother 2004; 54:849-853. A review of the impact of HAART on HIV-related opportunistic infections, with particular emphasis on clinical studies describing appropriate regimen combinations in patients with tuberculosis and HIV.
9. Day J, Grant A, Fielding K, et al. Does tuberculosis increase HIV load? J Infect Dis 2004; 190:1677-1684.
10. Dean G, Edwards S, Ives N, et al. Treatment of tuberculosis in HIV infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16:75-83.
11. Aaron L, Saadoun D, Calatroni I, et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect 2004; 10:388-398. A thorough update of this area, encompassing key issues such as co-administration of anti-TB therapeutics with HAART and TB prophylaxis in HIV-infected individuals.
12. Boyton R, Openshaw P. Pulmonary defences to acute respiratory infection. Br Med Bull 2002; 61:1-12.
13. French M, Price P, Stone S. Immune restoration disease after antiretroviral therapy. AIDS 2004; 18:1615-1627.
14. North R, Jung Y. Immunity to tuberculosis. Annu Rev Immunol 2004; 22:599-623. An update on current concepts in the immunopathogenesis of TB, with particular emphasis on murine models of immunity, from one of the leading groups in this field.
15. Condos R, Raju B, Canova A, et al. Recombinant gamma interferon stimulates signal transduction and gene expression in alveolar macrophages in vitro and in tuberculosis patients. Infect Immun 2003; 71:2058-2064.
16. Doherty T. New vaccines against tuberculosis. Trop Med Int Health 2004; 9:818-826.
17. Hoshino Y, Tse D, Rochford G, et al. Mycobacterium tuberculosis-induced CXCR4 and chemokine expression leads to preferential X4 HIV-1 replication in human macrophages. J Immunol 2004; 172:6251-6258.
18. Karakousis P, Moore R, Chaisson R. Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy. Lancet Infect Dis 2004; 4:557-565. The authors review current understanding of MAC in HIV-infected patients, with particular emphasis on prophylaxis, treatment regimens and future directions for research.
19. Feikin D, Feldman C, Schuchat A, Janoff E. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis 2004; 4:445-455. A comprehensive review of the recent literature on bacterial pneumonia in the developed and developing world, evaluating the impact of HAART and other treatments and concluding that HAART may have substantial potential to prevent bacterial pneumonia in Africa.
20. Hirschtick R, Glassroth J, Jordan M, et al. Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. N Engl J Med 1995; 333:845-851.
21. Chintu C, Bhat G, Walker A, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004; 364:1865-1871.
22. French N, Moore M, Haikala R, et al. A case-control study to investigate serological correlates of clinical failure of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults. J Infect Dis 2004; 190:707-712.
23. French N, Nakiyingi J, Carpenter L, et al. 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double blinded, randomised and placebo controlled trial. Lancet 2000; 355:2106-2111.
24. Jordano Q, Falco V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:1623-1628.
25. Lopez-Palomo C, Martin-Zamorano M, Benitez E, et al. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination. J Med Virol 2004; 72:517-524.
26. Klugman K, Madhi S, Huebner R, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N Engl J Med 2003; 349:1341-1348. A randomized, double-blind, prospective, clinical trial of enormous importance and implications: some 20,000 children at age 1-3 months in Soweto, South Africa, were immunized with a pneumococcal vaccine. A significantly reduced incidence of pneumonia was found in the immunized group.
27. Madhi S, Klugman K. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 2004; 10:811-813. A follow-up to the clinical vaccine trial described in [26], but here making the unanticipated observation that viral pneumonias are also very much reduced in children receiving the pneumococcal vaccine, arguing for an interplay in susceptibility and pathogenesis between bacterial and viral pathogens.
28. Thomas C, Limper A. Pneumocystis pneumonia. N Engl J Med 2004; 350: 2487-2498.
29. Morris A, Lundgren J, Masur H, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004; 10:1713-1720.
30. Chen F, Sethi G, Goldin R, et al. Concurrent granulomatous Pneumocystis carinii and Mycobacterium xenopi pneumonia: an unusual manifestation of HIV immune reconstitution disease. Thorax 2004; 59:997-999.
31. Lund F, Schuer K, Hollifield M, et al. Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P. carinii-specific antibody. J Immunol 2003; 171:1423-1430.
32. Kolls J, Habetz S, Shean M, et al. IFN-g and CD8+ T cells restore host defences against pneumocystis carinii in mice depleted of CD4+ T cells. J Immunol 1999; 162:2890-2894.
33. Wright T, Gigliotti F, Finkelstein J, et al. Immune mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999; 104:1307-1317.
34. Wright T, Pryhuber G, Chess P, et al. TNF receptor signalling contributes to chemokine secretion, inflammation, and respiratory deficits during Pneumocystis pneumonia. J Immunol 2004; 172:2511-2521.
35. Allister F, Chad S, Zheng M, et al. T cytotoxic-1 CD8+ T cells are effector cells against Pneumocystis in mice. J Immunol 2004; 172:1132-1138.
36. Salomon N, and Perlmann, DC. Cytomegalovirus pneumonia. Semin Respir Infect 1999; 14:353-358.
37. Benfield T, Helweg-Larsen J, Bang D, et al. Prognostic markers of short-term mortality in AIDS-associated Pneumocystis carinii pneumonia. Chest 2001; 119:844-851.
38. Graham S. Impact of HIV on childhood respiratory illness: differences between developing and developed countries. Pediatr Pulmonol 2003; 36: 462-468.
39. Springer KL, Weinberg A. Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity. J Antimicrob Chemother 2004; 54: 582-586.
40. Kaur A, Kassis N, Hale CL, et al. Direct relationship between suppression of virus-specific immunity and emergence of cytomegalovirus disease in simian AIDS. J Virol 2003; 77:5749-5758.